Fan Shaowei, Hu Yuanhui
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Cardiovasc Med. 2022 Jun 24;9:892113. doi: 10.3389/fcvm.2022.892113. eCollection 2022.
N6-methyladenosine (m6A) RNA methylation is one of the most common epigenetic modifications in RNA nucleotides. It is known that m6A methylation is involved in regulation, including gene expression, homeostasis, mRNA stability and other biological processes, affecting metabolism and a variety of biochemical regulation processes, and affecting the occurrence and development of a variety of diseases. Cardiovascular disease has high morbidity, disability rate and mortality in the world, of which heart failure is the final stage. Deeper understanding of the potential molecular mechanism of heart failure and exploring more effective treatment strategies will bring good news to the sick population. At present, m6A methylation is the latest research direction, which reveals some potential links between epigenetics and pathogenesis of heart failure. And m6A methylation will bring new directions and ideas for the prevention, diagnosis and treatment of heart failure. The purpose of this paper is to review the physiological and pathological mechanisms of m6A methylation that may be involved in cardiac remodeling in heart failure, so as to explain the possible role of m6A methylation in the occurrence and development of heart failure. And we hope to help m6A methylation obtain more in-depth research in the occurrence and development of heart failure.
N6-甲基腺苷(m6A)RNA甲基化是RNA核苷酸中最常见的表观遗传修饰之一。已知m6A甲基化参与调控,包括基因表达、体内稳态、mRNA稳定性及其他生物学过程,影响代谢和多种生化调控过程,并影响多种疾病的发生发展。心血管疾病在全球范围内具有高发病率、致残率和死亡率,其中心力衰竭是终末阶段。更深入了解心力衰竭的潜在分子机制并探索更有效的治疗策略将给患病群体带来福音。目前,m6A甲基化是最新的研究方向,它揭示了表观遗传学与心力衰竭发病机制之间的一些潜在联系。并且m6A甲基化将为心力衰竭的预防、诊断和治疗带来新的方向和思路。本文旨在综述m6A甲基化可能参与心力衰竭心脏重塑的生理和病理机制,以阐释m6A甲基化在心力衰竭发生发展中的可能作用。并且我们希望有助于m6A甲基化在心力衰竭发生发展方面获得更深入的研究。